No­vo Nordisk tries to tack­le Abl­ynx and bring it in­to the fold with a $3B buy­out of­fer, but the biotech keeps say­ing no

Play­ing a hot hand with a promis­ing late-stage as­set and a new­ly com­plet­ed $200 mil­lion IPO, Abl­ynx has waved away two bids by No­vo Nordisk …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA